In the second installment of our video series on the scientific and investment implications of COVID-19, Biotech Analyst Agustin Mohedas provides insights on how biotech and pharmaceutical companies are responding to the crisis, and why continued systematic testing for the virus is crucial to the eventual reopening and recovery of the U.S. economy.
- Early implementation of social distancing measures helped China and South Korea flatten the curve of COVID-19 relatively quickly. The pandemic trajectory in Europe and the U.S. is not comparable to Asia because both regions were slower to begin efforts to curtail the spread of the virus.
- While diagnostic companies have ramped up production of various testing methods, they remain limited by an overburdened health care system and the lack of personal protective equipment required to gather samples.
- Although the economic impact of social distancing is devastating, we believe reopening the economy prematurely without adequate testing procedures in place could cause a wider spread of the pandemic, leading to extended lockdowns and deeper long-term economic damage.
Subscribe for relevant insights delivered straight to your inbox